<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0379-3982</journal-id>
<journal-title><![CDATA[Revista Tecnología en Marcha]]></journal-title>
<abbrev-journal-title><![CDATA[Tecnología en Marcha]]></abbrev-journal-title>
<issn>0379-3982</issn>
<publisher>
<publisher-name><![CDATA[Instituto Tecnológico de Costa Rica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0379-39822024000400133</article-id>
<article-id pub-id-type="doi">10.18845/tm.v37i4.6939</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Papel del Mioinositol en la regulación hormonal femenina y el Síndrome de Ovario Poliquístico]]></article-title>
<article-title xml:lang=""><![CDATA[The role of Myo-Inositol in the regulation of female hormones and Polycystic Ovary Syndrome]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Loría]]></surname>
<given-names><![CDATA[Hazel Johanna]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vargas-Zúñiga]]></surname>
<given-names><![CDATA[Lester Fabian]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Vargas]]></surname>
<given-names><![CDATA[Joshua Andrey]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cordero-Robles]]></surname>
<given-names><![CDATA[Kristel Mariana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Urrea-Mayorga]]></surname>
<given-names><![CDATA[María José]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Tecnológico de Costa Rica  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Tecnológico de Costa Rica  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Tecnológico de Costa Rica  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Instituto Tecnológico de Costa Rica.  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Instituto Tecnológico de Costa Rica  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2024</year>
</pub-date>
<volume>37</volume>
<numero>4</numero>
<fpage>133</fpage>
<lpage>140</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_arttext&amp;pid=S0379-39822024000400133&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_abstract&amp;pid=S0379-39822024000400133&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_pdf&amp;pid=S0379-39822024000400133&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen Los inositoles son hexahidroxiciclohexanos conformados por nueve estereoisómeros, la mayoría biológicamente activos. La presente revisión pretende recapitular los principales efectos del mioinositol (MI) sobre las características patológicas del síndrome de ovario poliquístico (SOP) y su papel como regulador en la respuesta hormonal y bioquímica femenina. Las pacientes con SOP presentan trastornos clínicos, hormonales, metabólicos y fisiológicos que requieren tratamiento especializado a largo plazo. Por su parte, el inositol ha demostrado ser efectivo para reducir la severidad de los síntomas, regular la función menstrual y mejorar el perfil hormonal controlando parámetros metabólicos, por lo que su administración representa una opción efectiva para el manejo de los síntomas del SOP. A pesar de esto, existen limitaciones para los estudios como el hecho de que, al tratarse de un síndrome, el SOP es una condición heterogénea con una amplia variedad de síntomas y manifestaciones clínicas, por lo que también implica variedad de respuesta en las pacientes al MI. En los últimos años, su investigación ha generado evidencia terapéutica prometedora, pero aún falta abarcar más estudios controlados y doble ciego para definir su efecto según los fenotipos del SOP, así como investigaciones a largo plazo que evalúen la seguridad y eficacia del tratamiento en períodos prolongados. De manera general, el MI representa una alternativa efectiva y segura para el tratamiento del SOP, mostrando resultados similares a los presentados por otros tratamientos sin la presencia de los efectos secundarios conocidos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Inositols are hexahydroxycyclohexanes formed by nine stereoisomers, most of them biologically active. The present review aims to recapitulate the main effects of myo-inositol (MI) on the pathological characteristics of polycystic ovary syndrome (PCOS) and its role as a regulator of the female hormonal and biochemical response. Patients with PCOS present clinical, hormonal, metabolic and physiological disorders that require specialized long-term treatment. For its part, inositol has been shown to be effective in reducing the severity of symptoms, regulating menstrual function, and improving the hormonal profile by controlling metabolic parameters, so its administration represents an effective option for the management of symptoms. of PCOS. Despite this, there are limitations in the studies such as, being a syndrome, PCOS is a heterogeneous condition with a wide variety of symptoms and clinical manifestations, which is why it also implies a variety of responses in patients to MY treatment. In recent years, their research has generated promising therapeutic evidence, but there is still a need to cover more controlled and double-blind studies to define its effect according to PCOS phenotypes, as well as long-term research that evaluates the safety and effectiveness of the treatment over periods of time. Prolonged. In general, MI represents an effective and safe alternative for the treatment of PCOS, showing results like those presented by other treatments without the presence of known side effects.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[D-quiroinositol]]></kwd>
<kwd lng="es"><![CDATA[resistencia a la insulina]]></kwd>
<kwd lng="es"><![CDATA[hiperandrogenismo]]></kwd>
<kwd lng="es"><![CDATA[GLUT 4]]></kwd>
<kwd lng="es"><![CDATA[infertilidad]]></kwd>
<kwd lng="es"><![CDATA[hiperinsulinemia]]></kwd>
<kwd lng="es"><![CDATA[metformina]]></kwd>
<kwd lng="en"><![CDATA[D-chiro-inositol]]></kwd>
<kwd lng="en"><![CDATA[insulin resistance]]></kwd>
<kwd lng="en"><![CDATA[hyperandrogenism]]></kwd>
<kwd lng="en"><![CDATA[GLUT 4]]></kwd>
<kwd lng="en"><![CDATA[infertility]]></kwd>
<kwd lng="en"><![CDATA[hyperinsulinism]]></kwd>
<kwd lng="en"><![CDATA[metformin]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>(1)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies]]></article-title>
<source><![CDATA[Reprod. Health]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>(2)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Myo-Inositol and Its Derivatives: Their Emerging Role in the Treatment of Human Diseases]]></article-title>
<source><![CDATA[Front. Pharmacol]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>(3)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Inositols in PCOS]]></article-title>
<source><![CDATA[Molecules]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>(4)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mioinositol en combinación con D-chiro-inositol: resultados preliminares en el tratamiento de primera línea de pacientes con síndrome de ovario poliquístico]]></article-title>
<source><![CDATA[Ginecología y obstetricia de México]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>(5)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Inositol in Dermatologic Diseases]]></article-title>
<source><![CDATA[Acad. J. Health Sci. Med. Balear]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>(6)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Vasodilators for primary Raynaud&#8217;s phenomenon]]></article-title>
<source><![CDATA[Cochrane Database Syst. Rev]]></source>
<year>1858</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>(7)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Calcium-Dependent Ion Channels and the Regulation of Arteriolar Myogenic Tone]]></article-title>
<source><![CDATA[Front. Physiol]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>(8)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Diagnóstico e tratamento da calcifilaxia de pacientes com doença renal crônica]]></article-title>
<source><![CDATA[Braz. J. Nephrol]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>(9)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[First-time-in-human randomized clinical trial in healthy volunteers and haemodialysis patients with SNF472, a novel inhibitor of vascular calcification]]></article-title>
<source><![CDATA[Br. J. Clin. Pharmacol]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>(10)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Inositol Treatment for PCOS Should Be Science-Based and Not Arbitrary]]></article-title>
<source><![CDATA[Int. J. Endocrinol]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>(11)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Chapter 6 - Myo-inositol could restore peripheral inositol depletion induced by treatments for psychiatric and neurological conditions]]></article-title>
<source><![CDATA[Clinical Guide to Inositols, V. Unfer y D. Dewailly, Eds., Academic Press]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B12">
<label>(12)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Inositol induces mesenchymal-epithelial reversion in breast cancer cells through cytoskeleton rearrangement]]></article-title>
<source><![CDATA[Exp. Cell Res]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B13">
<label>(13)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Lifestyle management in polycystic ovary syndrome &#8211; beyond diet and physical activity]]></article-title>
<source><![CDATA[BMC Endocr. Disord]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B14">
<label>(14)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Treatment of polycystic ovary syndrome and its associated psychiatric symptoms with the Mongolian medicine Nuangong Qiwei Pill and macelignan]]></article-title>
<source><![CDATA[J. Ethnopharmaco]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B15">
<label>(15)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Potential role and therapeutic interests of myo-inositol in metabolic diseases]]></article-title>
<source><![CDATA[Biochimie]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B16">
<label>(16)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Contribution of myo-inositol and melatonin to human reproduction]]></article-title>
<source><![CDATA[Eur. J. Obstet. Gynecol. Reprod. Biol]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B17">
<label>(17)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cellular consequences of inositol depletion]]></article-title>
<source><![CDATA[Biochem. Soc. Trans]]></source>
<year>2009</year>
</nlm-citation>
</ref>
<ref id="B18">
<label>(18)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Crosstalks between Myo-Inositol Metabolism, Programmed Cell Death and Basal Immunity in Arabidopsis]]></article-title>
<source><![CDATA[PLOS ONE]]></source>
<year>2009</year>
</nlm-citation>
</ref>
<ref id="B19">
<label>(19)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Biosynthesis of inositol in rat testis homogenate]]></article-title>
<source><![CDATA[Biochem. Biophys. Res. Commun]]></source>
<year>1963</year>
</nlm-citation>
</ref>
<ref id="B20">
<label>(20)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The Biosynthesis of Free and Phosphatide Myo-inositol from Glucose by Mammalian Tissue Slices]]></article-title>
<source><![CDATA[J. Biol. Chem]]></source>
<year>1963</year>
</nlm-citation>
</ref>
<ref id="B21">
<label>(21)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The hormone-sensitive lipase C-60G polymorphism is correlated with recurrent spontaneous abortion in women with polycystic ovary syndrome]]></article-title>
<source><![CDATA[Gene Rep]]></source>
<year>1788</year>
</nlm-citation>
</ref>
<ref id="B22">
<label>(22)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Psychiatric disorders in women with polycystic ovary syndrome: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Endocrine]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B23">
<label>(23)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality]]></article-title>
<source><![CDATA[Hum. Reprod]]></source>
<year>2002</year>
</nlm-citation>
</ref>
<ref id="B24">
<label>(24)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The relationship between components of metabolic syndrome and plasma level of sex hormone-binding globulin]]></article-title>
<source><![CDATA[Eur. J. Transl. Myol]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B25">
<label>(25)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies]]></article-title>
<source><![CDATA[Reprod. Health]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B26">
<label>(26)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Contemporary Management of the Patient with Polycystic Ovary Syndrome]]></article-title>
<source><![CDATA[Obstetrics and Gynecology Clinics of North America]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B27">
<label>(27)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Dyslipidemia involvement in the development of polycystic ovary syndrome]]></article-title>
<source><![CDATA[Taiwan. J. Obstet. Gynecol]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B28">
<label>(28)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparison of effects of different statins on growth and steroidogenesis of rat ovarian theca-interstitial cells]]></article-title>
<source><![CDATA[Biol Reprod]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B29">
<label>(29)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Clinical evidence of statin therapy in non-dyslipidemic disorders]]></article-title>
<source><![CDATA[Pharmacol. Res]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B30">
<label>(30)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome]]></article-title>
<source><![CDATA[J. Clin. Pharmacol]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B31">
<label>(31)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Less is more: increased gonadotropin use for ovarian stimulation adversely influences clinical pregnancy and live birth after in vitro fertilization]]></article-title>
<source><![CDATA[Fertil. Steril.]]></source>
<year>2007</year>
</nlm-citation>
</ref>
<ref id="B32">
<label>(32)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study]]></article-title>
<source><![CDATA[Gynecol. Endocrinol]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B33">
<label>(33)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance]]></article-title>
<source><![CDATA[Gynecol. Endocrinol]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B34">
<label>(34)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials]]></article-title>
<source><![CDATA[Endocr. Connect]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B35">
<label>(35)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetes]]></article-title>
<source><![CDATA[Open Heart]]></source>
<year>1989</year>
</nlm-citation>
</ref>
<ref id="B36">
<label>(36)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis]]></article-title>
<source><![CDATA[Reprod. Health]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B37">
<label>(37)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials]]></article-title>
<source><![CDATA[Arch. Gynecol. Obstet]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B38">
<label>(38)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Chapter 10 - Use of myo-inositol in the treatment of PCOS symptoms in adolescents]]></article-title>
<source><![CDATA[Clinical Guide to Inositols, V. Unfer y D. Dewailly, Eds., Academic Press]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B39">
<label>(39)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Chapter 11 - Inositols and other supplements in the management of PCOS]]></article-title>
<source><![CDATA[Polycystic Ovary Syndrome, E. Diamanti-Kandarakis, Ed., Elsevier]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B40">
<label>(40)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials]]></article-title>
<source><![CDATA[Reprod. Biol. Endocrinol]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B41">
<label>(41)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Chronotype: A Tool to Screen Eating Habits in Polycystic Ovary Syndrome?]]></article-title>
<source><![CDATA[Nutrients]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B42">
<label>(42)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Myoinositol Versus Metformin in the Treatment of Polycystic Ovarian Syndrome: A Systematic Review]]></article-title>
<source><![CDATA[Cureus]]></source>
<year>1748</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
